- Loose stools
- Abdominal pain
- Elevated serum transaminase levels (rare)
- Hypersensitivity to the drug
- Diabetic ketoacidosis
- Ulcerative colitis
- Partial intestinal obstruction
- Chronic intestinal diseases
- Hepatic impairment
- Severe renal impairment
- History of abdominal surgery
- Mild to moderate renal impairment
- Monitor hepatic function tests during therapy
- Enhance hypoglycaemic effects of sulfonylureas. Give glucose in such situations.
Interaction: Sucrose: Abdominal discomfort or diarrhoea. Digestive enzymes (amylase, pancreatin) and intestinal adsorbents (charcoal): Reduce efficacy of acarbose. Sulphonylureas, biguanides: Acarbose increases their efficacy. Insulin: In IDDM, insulin requirement is reduced.
Servings: Oral: Start with 25mg thrice daily with the 1st bite of each main meal. Increased to 50mg thrice daily; at 4 to 8 week intervals based on 1st hour postprandial glucose levels and tolerance. Then increased to 100mg thrice daily if required. Maintenance dosage: 50mg to 100mg thrice daily; depending up on the patient`s weight. Maximum dose: 200mg thrice daily.